138 related articles for article (PubMed ID: 8098891)
1. Long-term treatment of macroprolactinomas with CV 205-502.
Kvistborg A; Halse J; Bakke S; Bjøro T; Hansen E; Djøseland O; Brownell J; Jervell J
Acta Endocrinol (Copenh); 1993 Apr; 128(4):301-7. PubMed ID: 8098891
[TBL] [Abstract][Full Text] [Related]
2. The efficacy and tolerability of CV 205-502 (a nonergot dopaminergic drug) in macroprolactinoma patients and in prolactinoma patients intolerant to bromocriptine.
van der Lely AJ; Brownell J; Lamberts SW
J Clin Endocrinol Metab; 1991 May; 72(5):1136-41. PubMed ID: 1673685
[TBL] [Abstract][Full Text] [Related]
3. CV 205-502 treatment of macroprolactinomas.
Crottaz B; Uske A; Reymond MJ; Rey F; Siegel RA; Brownell J; Gomez F
J Endocrinol Invest; 1991 Oct; 14(9):757-62. PubMed ID: 1684803
[TBL] [Abstract][Full Text] [Related]
4. Effect of the new dopaminergic agonist CV 205-502 on plasma prolactin levels and tumour size in bromocriptine-resistant prolactinomas.
Duranteau L; Chanson P; Lavoinne A; Horlait S; Lubetzki J; Kuhn JM
Clin Endocrinol (Oxf); 1991 Jan; 34(1):25-9. PubMed ID: 1672268
[TBL] [Abstract][Full Text] [Related]
5. Comparison among different dopamine-agonists of new formulation in the clinical management of macroprolactinomas.
Colao A; Merola B; Sarnacchiaro F; Di Sarno A; Landi ML; Marzullo P; Cerbone G; Ferone D; Lombardi G
Horm Res; 1995; 44(5):222-8. PubMed ID: 8582715
[TBL] [Abstract][Full Text] [Related]
6. Long-term treatment of bromocriptine-intolerant prolactinoma patients with CV 205-502.
Glaser B; Nesher Y; Barziliai S
J Reprod Med; 1994 Jun; 39(6):449-54. PubMed ID: 7932398
[TBL] [Abstract][Full Text] [Related]
7. [Treatment of prolactinoma with a new dopamine agonist].
Svoboda T; Luger A; Knosp E; Geyer G
Dtsch Med Wochenschr; 1991 Aug; 116(33):1224-7. PubMed ID: 1678695
[TBL] [Abstract][Full Text] [Related]
8. Treatment of macroprolactinomas with a new non-ergot, long-acting dopaminergic drug, CV 205-502.
van't Verlaat JW; Croughs RJ; Brownell J
Clin Endocrinol (Oxf); 1990 Nov; 33(5):619-24. PubMed ID: 1979262
[TBL] [Abstract][Full Text] [Related]
9. Endocrine function, psychiatric and clinical consequences in patients with macroprolactinomas after long-term treatment with the new non-ergot dopamine agonist CV205-502.
Barnett PS; Palazidou E; Miell JP; Coskeran PB; Butler J; Dawson JM; Maccabe J; McGregor AM
Q J Med; 1991 Nov; 81(295):891-906. PubMed ID: 1687293
[TBL] [Abstract][Full Text] [Related]
10. Effects of the dopamine agonist CV 205-502 in human prolactinomas resistant to bromocriptine.
Brue T; Pellegrini I; Gunz G; Morange I; Dewailly D; Brownell J; Enjalbert A; Jaquet P
J Clin Endocrinol Metab; 1992 Mar; 74(3):577-84. PubMed ID: 1346788
[TBL] [Abstract][Full Text] [Related]
11. Positive response to compound CV 205-502 in hyperprolactinemic patients resistant to or intolerant of bromocriptine.
Merola B; Sarnacchiaro F; Colao A; Di Somma C; Di Sarno A; Ferone D; Selleri A; Landi ML; Schettini G; Nappi C
Gynecol Endocrinol; 1994 Sep; 8(3):175-81. PubMed ID: 7847102
[TBL] [Abstract][Full Text] [Related]
12. A double-blind study comparing a new non-ergot, long-acting dopamine agonist, CV 205-502, with bromocriptine in women with hyperprolactinaemia.
Homburg R; West C; Brownell J; Jacobs HS
Clin Endocrinol (Oxf); 1990 May; 32(5):565-71. PubMed ID: 1973085
[TBL] [Abstract][Full Text] [Related]
13. Ophthalmic results in patients with macroprolactinomas treated with a new prolactin inhibitor CV 205-502.
Grochowicki M; Khalfallah Y; Vighetto A; Berquet S; Sassolas G
Br J Ophthalmol; 1993 Dec; 77(12):785-8. PubMed ID: 7906538
[TBL] [Abstract][Full Text] [Related]
14. Treatment of prolactin-secreting pituitary macroadenomas with the long-acting non-ergot dopamine agonist CV 205-502.
Vance ML; Lipper M; Klibanski A; Biller BM; Samaan NA; Molitch ME
Ann Intern Med; 1990 May; 112(9):668-73. PubMed ID: 1970714
[TBL] [Abstract][Full Text] [Related]
15. Parlodel LAR in the treatment of macroprolactinomas.
Kocijancic A; Prezelj J; Vrhovec I; Lancranjan I
Acta Endocrinol (Copenh); 1990 Feb; 122(2):272-6. PubMed ID: 2316314
[TBL] [Abstract][Full Text] [Related]
16. CV 205-502, a new dopamine agonist, versus bromocriptine in the treatment of hyperprolactinaemia.
van der Heijden PF; de Wit W; Brownell J; Schoemaker J; Rolland R
Eur J Obstet Gynecol Reprod Biol; 1991 Jul; 40(2):111-8. PubMed ID: 1676973
[TBL] [Abstract][Full Text] [Related]
17. [Treatment of macroprolactinomas with quinagolide (Norprolac)].
Tabarin A; Catargi B
Ann Endocrinol (Paris); 1997; 58(2):87-94. PubMed ID: 9239226
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of quinagolide in resistance to dopamine agonists: results of a multicenter study. Club de l'Hypophyse.
Rohmer V; Freneau E; Morange I; Simonetta C
Ann Endocrinol (Paris); 2000 Nov; 61(5):411-7. PubMed ID: 11084391
[TBL] [Abstract][Full Text] [Related]
19. Prolactinomas resistant to standard dopamine agonists respond to chronic cabergoline treatment.
Colao A; Di Sarno A; Sarnacchiaro F; Ferone D; Di Renzo G; Merola B; Annunziato L; Lombardi G
J Clin Endocrinol Metab; 1997 Mar; 82(3):876-83. PubMed ID: 9062500
[TBL] [Abstract][Full Text] [Related]
20. Prolactinomas resistant to bromocriptine: long-term efficacy of quinagolide and outcome of pregnancy.
Morange I; Barlier A; Pellegrini I; Brue T; Enjalbert A; Jaquet P
Eur J Endocrinol; 1996 Oct; 135(4):413-20. PubMed ID: 8921822
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
